Maintenance intravenous iron therapy in hemodialysis patients receiving recombinant human erythropoietin

Abstract EN

Iron Supplementation is crucial in raising hematocrit as well as dosage saving for recombinant human erythropoietin therapy (rHuEPO) in maintenance hemodialysis patients.

Intravenous iron has proved to be both safe and efficacious in this patient's population.

However, the exact iron requirement has not been worked our.

In this study we found that 1000 mg of element iron (given as iron saccharate) per moth was effective in maintaining hematocrit and hemoglobin at 33% and 110 gm/L respectively, and reducing the erythropoietin (EPO) dosage by about 20% in maintenance hemodialysis patients who were iron-replete.

The serum ferritin increased from 219±144 to 320±234 µg/L (P<0.05).

There were no major side effects and patients tolerated the monthly iron therapy well.

Our study suggests that intravenous iron saccharate (100 mg/month) is effective and safe in patients on maintenance hemodialysis receiving RHUEPO.